![Page 1: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/1.jpg)
An Integrative Personalized Approach to Diagnostics and Drug Discovery
![Page 2: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/2.jpg)
Powering Precision Medicine
What We Do
Our world-class algorithms enable us to analyze
genetic mutations and produce the most precise
diagnostics available for the patient. We also
collaborate with Pharma to accelerate drug
repurposing & discovery for a variety of diseases
![Page 3: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/3.jpg)
The Process
Step 1: Sample Preparation
We obtain the DNA of the patient through a painless
saliva sample
Step 2: Sequencing
Our partner, BGI, sequences the exome of the patient
to identify genes that might be responsible for disease
and these proteins serve as our drug targets
Step 3: Physicians and Pharma
We recommend treatment options to the patient’s
physician and/or partner with Pharma on the novel
compound, reducing time to patient utilization
![Page 4: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/4.jpg)
A Two-Sided Approach to Personalized Medicine
Exome sequencing and interpretation, including prediction
of disease-associated mutations, drug selection & avoidance, and drug
metabolism
Utilizing our algorithms to identify existing and new compounds that
can treat disease-causing mutations.
Partner with Pharma to accelerate drug repurposing & discovery
Diagnostics Precision Medicine
![Page 5: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/5.jpg)
Our Algorithms
Prognostix
Dr. Prodis
Findsite
Prognostix is the first algorithm capable of covering whole exomes, and
uses 3D protein structure to make more precise predictions about a DNA
mutation’s possible pathogenicity
Dr. Prodis makes predictions of protein structure, ligand binding sites, prediction of FDA binding
drugs, side effects and toxicity for 86% of the human proteome
Findsite utilizes ligand homology screening; it is industry leading and capable of predicting structures of a
large portion of the human proteome, allowing high-throughput drug screening
![Page 6: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/6.jpg)
Comparison of Prognostix to Other Algorithms
AccuracyPrognostix significantly outperforms competing algorithms:
MCC
• the ability of the algorithm to correctly sort pathogenic mutations from non-
pathogenic
AUC
• the ratio of true positives to false positives
Accuracy
• the ability to correctly identify pathogenic mutations
When run on a 1K genome with 150,000 mutations, the false positive rate was <10%, which is significantly lower than other methods
See Appendix A
![Page 7: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/7.jpg)
Comparison of Findsite to Other Algorithms
See Appendix B
25.6 compounds/hour
Speed
• When screened across a 325 bp
protein, FINDSITEcomb was able
to screen 1000 compounds in 30
hours
Accuracy
• When screening proteins against
true matching ligands, decoy
ligands, and unrelated ligands,
Findsite will correctly identify more
true matching ligands for a protein
in the top 1% of identified ligands
as compared to competitive
methods
• The ratio of true positives to false
positives is significantly higher than
competiting methods
167x faster than DOCK 6
33x faster than AUTODOCKvina
![Page 8: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/8.jpg)
Partnership with BGI
Enhanced Accelerated Exome – Launched November 2014
• Combine BGI's infrastructure with expertise of Intellimedix to offer both NGS analysis and genome-wide diagnostic interpretation faster than current industry norms
• Provide extremely fast turnaround with a high quality product
– More comprehensive analysis than currently available in the market
– Researchers - and soon clinicians - will be able to leverage service to gain detailed understanding of patient-specific genetic conditions
• Redefine customer service in exome marketplace, setting a new standard across the genomic sequencing and interpretation industry
• Save time and increase the specificity of analysis, giving patients better diagnostics, and eventually, more successful therapeutics
![Page 9: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/9.jpg)
Our Competitive Advantage
Speed to results: 10 day
turnaround (vs 8 weeks)
Accuracy: 3x lower rate of
false positives
Greater coverage: 80%
exome coverage (vs 30%)
Accuracy and coverage: higher than existing standards
Time compression: algorithms, FDA-approved drugs
Diagnostics Precision Medicine
![Page 10: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/10.jpg)
Intellimedix Current Applications
High-Throughput Screening Approach Currently Being Used for Epilepsy (Dravet) and Mitochondrial Disorders
Dr. PRODIS Analysis & Screening
Gene Sequencing& PROGNOSTIX
In VitroScreening
Clinical Trials
• In silico screening of FDA and non-FDA approved compounds
• Predictions of potential efficacy, side effects and toxicity
• High-throughput screening of drugs in personalized in vitromodels (IPSCS) and single cell models to confirm activity on predicted molecular targets
• Phase I or Phase II clinical trials of most promising drugs
• Genome and ExomeSequencing
• Prognostix tool for identification of known and possible disease-causing mutations
![Page 11: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/11.jpg)
Proof of Concept and Intellectual Property
• 2 repurposed drugs for Chronic
Fatigue Syndrome
• 4 repurposed drugs for Dravet
Syndrome
• Provisional patents for 52 anti-
Ebola molecules
• Other patents pending
Unique Assets & Capabilities
• Exclusive software license of our
algorithms
Partners & Collaborators
• BGI – gene sequencing; cancer panel
and drug repurposing; Alzheimer’s
diagnostic
• Pfizer/EF – precision drug discovery for
epilepsy
• CDC/Emory University – anti-Ebola
compounds
Our Proof of Concept
![Page 12: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/12.jpg)
Accelerating Timeline
Series A Financing
Pfizer/EF Project
Virus Collaboration
Exome Product
BGI Partnership
4 Novel AED Compounds Discovered
GA Tech License
Dravet Research
Kytril Discovery
Algorithms
2012 2013 2014 2015
![Page 13: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/13.jpg)
The Team
Jim RichardsPresident & CEO
Jeffery Skolnick, PhDDirector Systems Biology at
Georgia Tech; 325 publications; Google Scholar h-index: 73
Harvey Kupferberg, PharmD, PhD
Leader of NIH’s Antiepileptic Drug Development program
![Page 14: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/14.jpg)
Partners
![Page 15: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/15.jpg)
The Business Model
Diagnostics:
• Diagnostic report for patients (disease prediction, drug selection & avoidance, drug metabolism, etc)
Precision Medicine:
• Scientific services to pharma (Pfizer/Epilepsy Foundation)
• Royalty on drugs repurposed or developed
![Page 16: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/16.jpg)
Financial Projections
Intellimedix Projected Income Statement
Year
$ Amounts in Millions 2015 2016 2017 2018 2019
Revenue:
Diagnostics Revenue $0.3 $1.7 $8.0 $35.0 $60.0
Precision Medicine Revenues $0.3 $1.0 $4.0 $7.0 $10.5
Total Revenues $0.6 $2.7 $12.0 $42.0 $70.5
Total Cost of Goods Sold $0.2 $1.3 $6.6 $25.9 $44.5
Gross Margin $0.3 $1.4 $5.5 $16.2 $26.1
Total Operating Expenses $1.0 $1.7 $2.9 $4.0 $4.7
EBITDA ($0.6) ($0.5) $2.6 $12.2 $21.4
Cash Flow ($0.6) ($0.5) $1.9 $11.5 $20.4
![Page 17: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/17.jpg)
![Page 18: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/18.jpg)
Appendix A
0 0.2 0.4 0.6 0.8 1
PROGNOSTIX
SIFT
PPH2_HDIV
MUTATIONASSESSOR*
FATHMM*
PredictSNP Benchmark Set
AUC Accuracy MCC
Method # of Mutations False PositiveRate
PROGNOSTIX 156,273 6.68%
SIFT 147,808 35.6%PPH2_HDIV 147,792 48.9%MUTATIONASSESSOR* 145,062 28.2%
FATHMM* 130,043 13.6%
![Page 19: An Integrative Personalized Approach to Diagnostics and ...diagnostics available for the patient. We also ... Prognostix significantly outperforms competing algorithms: MCC ... –](https://reader035.vdocuments.site/reader035/viewer/2022071104/5fde34551b1a9354076fcfba/html5/thumbnails/19.jpg)
Appendix B
average EF0.01,
23.1
0 20 40
DOCK 6
AUTODO…
FINDSITEc…
EF 0.01
# True Binding Compounds Found in Top 1%
AUAC, 0.77
0 0.2 0.4 0.6 0.8 1
DOCK 6
FLEXX
ICM
PhDOCK
SURFLEX
FINDSITEcomb
AUAC
Ratio of True Positives to False Positives